Abciximab
- Generic Name
- Abciximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143653-53-6
- Unique Ingredient Identifier
- X85G7936GV
- Background
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (Ī±vĪ²3) receptor found on platelets and vess...
- Indication
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended ...
- Associated Conditions
- Ischemic cardiovascular events
- Associated Therapies
- -
A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Laval University
- Target Recruit Count
- 105
- Registration Number
- NCT00440778
- Locations
- šØš¦
Laval Hospital, Quebec, Canada
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 429
- Registration Number
- NCT00426751
- Locations
- š©šŖ
GSK Investigational Site, Homburg, Saarland, Germany
Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2009-06-23
- Lead Sponsor
- Charles University, Czech Republic
- Target Recruit Count
- 80
- Registration Number
- NCT00420030
- Locations
- šØšæ
Cardiocenter, University Hospital Vinohrady, Prague, Czech Republic
FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab
- Conditions
- Interventions
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2008-01-16
- Lead Sponsor
- University of Bologna
- Target Recruit Count
- 692
- Registration Number
- NCT00383136
- Locations
- š®š¹
Laboratorio Di Emodinamica, Istituto Di Cardiologia, Azienda Ospedaliera S.Orsola Malpighi, Bologna, BO, Italy
š®š¹Divisione Di Cardiologia Ii, Ospedale Policlinico Le Molinette, Torino, TO, Italy
š®š¹Divisione Di Cardiologia, Ospedale Maggiore, Bologna, BO, Italy
Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients
- Conditions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2013-09-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 220
- Registration Number
- NCT00379418
- Locations
- šŗšø
Emory University Hospital, Atlanta, Georgia, United States
šŗšøAtlanta VA Medical Center, Atlanta, Georgia, United States
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 110
- Registration Number
- NCT00354406
- Locations
- š®š¹
Cardiothoracic Department, Ospedale Cisanello, Pisa, Italy
Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2006-05-16
- Lead Sponsor
- Azienda Sanitaria Ospedaliera
- Target Recruit Count
- 84
- Registration Number
- NCT00320229
- Locations
- š®š¹
Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
- Conditions
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 2792
- Registration Number
- NCT00269880
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
- Conditions
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 2038
- Registration Number
- NCT00269893
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
- Conditions
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 1265
- Registration Number
- NCT00269906
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.